Qualitiy of life-scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: an analysis of the HIDIT-II trial

Chronic Hepatitis D (CHD) is caused by co-infection with the hepatitis delta virus (HDV) of individuals with hepatitis B virus infection (HBV, CHB). It is considered the most severe form of viral hepatitis, promoting liver fibrosis, cirrhosis and hepatocellular carcinoma. Additionally, CHD has shown to cause worse patient related outcomes as compared to CHB alone. Until recently, only pegylated interferon based therapeutic schemes were available for treatment of CHD.